

Amendments to the Claims:

This listing of claims replaces all prior versions and listings of claims in the application:

Listing of Claims:

1. (previously presented) A method of preventing or treating skin conditions characterized by increased T cell activation and abnormal antigen presentation in the dermis and epidermis, comprising the step of administering to a mammal an agent which binds to LFA-3 or CD2 selected from the group consisting of a CD2 polypeptide, an LFA-3 polypeptide, an anti-CD2 antibody homolog, and an anti-LFA-3 antibody homolog, in combination with a therapy selected from the group consisting of PUVA, chemotherapy and UV light.
2. (previously presented) The method according to claim 1, wherein the condition is selected from the group consisting of atopic dermatitis, cutaneous T cell lymphoma such as mycosis fungoides, allergic and irritant contact dermatitis, lichen planus, alopecia areata, pyoderma gangrenosum, vitiligo, ocular cicatricial pemphigoid, and urticaria.
3. (previously presented) The method according to claim 1, wherein the condition is psoriasis.
4. (previously presented) The method according to claim 1, wherein the agent is selected from the group consisting of an anti-LFA-3 antibody homolog, and a soluble CD2 polypeptide.

5. (previously presented) The method according to claim 1, wherein the agent is selected from the group consisting of anti-CD2 antibody homolog and soluble LFA-3 polypeptide.

6. (previously presented) The method according to claim 5, wherein said soluble LFA-3 polypeptide is a soluble LFA-3 polypeptide fused to all or part of an immunoglobulin heavy chain hinge region and all or part of a heavy chain constant region.

7. (currently amended) The method according to claim 6, wherein said soluble LFA-3 polypeptide is LFA3TIP (amino acids 1-319 of SEQ ID NO:8).

8. (previously presented) The method according to claim 4, wherein the agent is an anti-LFA-3 antibody homolog.

9. (previously presented) The method according to claim 5, wherein the agent is an anti-CD2 antibody homolog.

10. (previously presented) The method according to claim 8, wherein the agent is a monoclonal anti-LFA-3 antibody.

11. (previously presented) The method according to claim 9, wherein the agent is a monoclonal anti-CD2 antibody.

12. (previously presented) The method according to claim 10, wherein the agent is a monoclonal anti-LFA-3 antibody produced by a hybridoma selected from the group consisting of hybridomas having Accession Nos. ATCC HB 10693 (1E6), ATCC HB 10694 (HC-1B11), ATCC HB 10695 (7A6), and ATCC HB 10696 (8B8).

13. (previously presented) The method according to claim 12, wherein the monoclonal anti-LFA-3 antibody is produced by a hybridoma selected from the group of hybridomas having Accession Nos. ATCC HB 10695 (7A6) and ATCC HB 10693 (1E6).

14. (previously presented) The method according to claim 8, wherein the agent is a chimeric recombinant anti-LFA-3 antibody homolog.

15. (previously presented) The method according to claim 9, wherein the agent is a chimeric recombinant anti-CD2 antibody homolog.

16. (previously presented) The method according to claim 8, wherein the agent is a humanized recombinant anti-LFA-3 antibody homolog.

17. (previously presented) The method according to claim 9, wherein the agent is a humanized recombinant anti-CD2 antibody homolog.

18. (previously presented) The method according to claim 8, wherein the agent is selected from the group consisting of an Fab fragment, an Fab' fragment, an F(ab')₂ fragment, an F(v) fragment and an intact immunoglobulin heavy chain of an anti-LFA-3 antibody homolog.

19. (previously presented) The method according to claim 9, wherein the agent is selected from the group consisting of an Fab fragment, an Fab' fragment, an F(ab')₂ fragment, an F(v) fragment and an intact immunoglobulin heavy chain of an anti-CD2 antibody homolog.

20. (previously presented) The method according to claim 5, wherein the agent is a soluble LFA-3 polypeptide.

21. (previously presented) The method according to claim 4, wherein the agent is a soluble CD2 polypeptide.

22. (previously presented) The method according to claim 20, wherein the agent is a soluble LFA-3 polypeptide selected from the group of polypeptides consisting of AA₁-AA₉₂ of SEQ ID NO:2, AA₁-AA₈₀ of SEQ ID NO:2, AA₅₀-AA₆₅ of SEQ ID NO:2, and AA₂₀-AA₈₀ of SEQ ID NO:2.

23. (previously presented) The method according to claim 1, wherein the mammal is a human.

24. (previously presented) The method according to claim 1, wherein the agent is administered at a dose between about 0.001 and about 50 mg agent per kg body weight.

25. (previously presented) The method according to claim 24, wherein the agent is administered at a dose between about 0.01 and about 10 mg agent per kg body weight.

26. (previously presented) The method according to claim 24, wherein the agent is administered at a dose between about 0.1 and about 4 mg agent per kg body weight.

27. (previously presented) The method according to claim 24, wherein the dose is administered once to three times per week.

28. (previously presented) The method according to claim 24, wherein the dose is administered once to three times per day.

29. (previously presented) The method according to claim 28, wherein the dose is administered about one to three times daily for between 3 and 7 days.

30. (previously presented) The method according to claim 29, wherein the dose is administered about one to three times daily for between 3 and 7 days on a monthly basis.

31. (previously presented) The method according to claim 1, wherein the agent is administered intravenously, intramuscularly, subcutaneously, intra-articularly, intrathecally, periostally, intratumorally, intralesionally, perilesionally by infusion, orally, topically or by inhalation.

32. (previously presented) The method according to claim 31, wherein the agent is administered intramuscularly, intravenously or subcutaneously.

33. (previously presented) The method according to claim 4, wherein the agent is linked to one or more members independently selected from the group consisting of anti-LFA-3 antibody homologs, soluble CD2 polypeptides, cytotoxic agents and pharmaceutical agents.

34. (previously presented) The method according to claim 5, wherein the agent is linked to one or more members independently selected from the group consisting of anti-CD2 antibody homologs, soluble LFA-3 polypeptides, cytotoxic agents and pharmaceutical agents.

35. (previously presented) The method according to claim 34, wherein the agent is a polypeptide consisting of a soluble LFA-3 polypeptide linked to an immunoglobulin hinge and heavy chain constant region or portions thereof.

36. (currently amended) The method according to claim 35, wherein said polypeptide is LFA3TIP (amino acids 1-319 of SEQ ID NO:8).

37. (previously presented) The method according to claim 1, wherein the condition is UV damage.

38. (previously presented) A method of preventing or treating psoriasis comprising the step of administering to a mammal a composition comprising an agent which binds to LFA-3 or CD2 selected from the group consisting of a CD2 polypeptide, an LFA-3 polypeptide, an anti-CD2 antibody homolog, and an anti-LFA-3 antibody homolog, in combination with a therapy selected from the group consisting of PUVA, chemotherapy and UV light.

39. (previously presented) The method of claim 38, wherein said agent is a CD2 polypeptide.

40. (previously presented) The method of claim 39, wherein said CD2 polypeptide is a soluble CD2 polypeptide.

41. (previously presented) The method of claim 38, wherein said agent is an LFA-3 polypeptide.

42. (previously presented) The method of claim 41, wherein said LFA-3 polypeptide is a soluble LFA-3 polypeptide.

43. (previously presented) The method of claim 42, wherein said soluble LFA-3 polypeptide is a soluble LFA-3 polypeptide fused to all or part of an immunoglobulin heavy chain hinge region and all or part of a heavy chain constant region.

44. (currently amended) The method of claim 43, wherein said soluble LFA-3 polypeptide is LFA3TIP (amino acids 1-319 of SEQ ID NO:8).

45. (previously presented) The method of claim 38, wherein said agent is an anti-CD2 antibody homolog.

46. (previously presented) The method of claim 45, wherein said anti-CD2 antibody homolog is a humanized recombinant anti-CD2 antibody homolog or chimeric recombinant anti-CD2 antibody homolog.

47. (previously presented) The method of claim 38, wherein said agent is an anti-LFA-3 antibody homolog.

48. (previously presented) The method of claim 47, wherein said anti-LFA-3 antibody homolog is a humanized recombinant anti-LFA-3 antibody homolog or chimeric recombinant anti-LFA-3 antibody homolog.

49. (previously presented) The method according to claim 38, wherein the agent is a soluble LFA-3 polypeptide selected from the group consisting of AA₁-AA₉₂ of SEQ ID NO:2, AA₁-AA₈₀ of SEQ ID NO:2, AA₅₀-AA₆₅ of SEQ ID NO:2, and AA₂₀-AA₈₀ of SEQ ID NO:2.

50. (previously presented) The method according to claim 38, wherein the mammal is a human.

51. (previously presented) The method of claim 1, wherein the therapy is UV light therapy.

52. (previously presented) The method of claim 38, wherein the therapy is UV light therapy.

53. (previously presented) A method of preventing or treating psoriasis comprising the step of administering to a mammal a composition comprising a soluble LFA-3 polypeptide fused to all or part of an immunoglobulin heavy chain region and all or part of a heavy chain constant region in combination with UV light therapy.

54. (currently amended) The method of claim 53, wherein said soluble LFA-3 polypeptide is LFA3TIP (amino acids 1-319 of SEQ ID NO:8).

55. (previously presented) The method according to claim 6, wherein said soluble LFA-3 polypeptide comprises AA₁-AA₉₂ of SEQ ID NO:2 fused to a portion of a human IgG1 hinge region and the CH2 and CH3 regions of an IgG₁ heavy chain constant domain.

56. (currently amended) The method according to claim 43 ~~[[44]]~~, wherein said soluble LFA-3 polypeptide comprises AA₁-AA₉₂ of SEQ ID NO:2 fused to a portion of a human IgG1 hinge region and the CH2 and CH3 regions of an IgG₁ heavy chain constant domain.

57. (previously presented) The method according to claim 53, wherein said soluble LFA-3 polypeptide comprises AA₁-AA₉₂ of SEQ ID NO:2 fused to a portion of a human IgG1 hinge region and the CH2 and CH3 regions of an IgG₁ heavy chain constant domain.